A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in ...
Dec 6, 2001 · A total of 5010 patients with heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned to receive 160 mg of valsartan or placebo twice daily.
Valsartan Heart FailureTrial - Val-HeFT - American College of …
Jan 1, 2001 · A total of 5010 patients with heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned to receive 160 mg of valsartan or placebo twice daily.
Valsartan: in chronic heart failure - PubMed
Results from the Valsartan Heart Failure Trial (Val-HeFT) showed that in patients with chronic heart failure (CHF) [n = 5010], valsartan 160 mg twice daily, when used in combination with …
Effect of the Angiotensin Receptor Blocker Valsartan on Morbidity …
Nov 21, 2000 · In order to assess the efficacy of the angiotensin receptor blocker valsartan in the treatment of heart failure (HF), 5010 patients were studied in 16 countries on 4 continents.
Effect of Valsartan on hospitalization: results from Val-HeFT
Methods: Val-HeFT was a randomized, double-blind parallel-arm study in which HF patients (New York Heart Association class II-IV) received either valsartan (n = 2511, force-titrated to 160 mg …
Effects of valsartan on morbidity and mortality in patients with …
Val-HeFT has provided the first placebo-controlled outcome data demonstrating a favorable effect of an angiotensin receptor blocker on mortality and morbidity in patients with HF not treated …
Val-HeFT: changing the heart failure horizon - Oxford Academic
Apr 1, 2003 · The Valsartan Heart Failure Trial (Val-HeFT) established that the angiotensin receptor blocker valsartan is effective for reducing morbidity and slowing the progression of …
[Clinical study of the month. Effects of valsartan in chronic heart ...
The Valsartan Heart Failure Trial (Val-HeFT) tested the efficacy of the angiotensin-receptor blocker valsartan in addition to prescribed therapy. A total of 5010 patients with heart failure of …
The Role of Angiotensin Receptor Blockade: Further Insights From Val-HeFT
Dec 2, 2002 · The overall results of Val-HeFT showed that valsartan (titrated to 160 mg twice daily) improved heart failure morbidity and slowed the progression of disease compared with …
Val-HeFT - Wiki Journal Club
Aug 24, 2014 · The 2001 Valsartan Heart Failure Trial (Val-HeFT) provided an interesting window to the role of ARB therapy in HFrEF. The trial randomized 5,010 with LVEF <40% to valsartan …